![PDF) N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: A double blind randomised placebo controlled trial targeting negative symptoms PDF) N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: A double blind randomised placebo controlled trial targeting negative symptoms](https://www.researchgate.net/profile/Michael-Berk-2/publication/308133049/figure/fig2/AS:408131587854336@1474317561232/Study-Outline_Q320.jpg)
PDF) N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: A double blind randomised placebo controlled trial targeting negative symptoms
![Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia - Caitlin OB Yolland, Donal Hanratty, Erica Neill, Susan L Rossell, Michael Berk, Olivia M Dean, David J Castle, Eric Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia - Caitlin OB Yolland, Donal Hanratty, Erica Neill, Susan L Rossell, Michael Berk, Olivia M Dean, David J Castle, Eric](https://journals.sagepub.com/cms/10.1177/0004867419893439/asset/images/large/10.1177_0004867419893439-fig1.jpeg)
Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia - Caitlin OB Yolland, Donal Hanratty, Erica Neill, Susan L Rossell, Michael Berk, Olivia M Dean, David J Castle, Eric
![Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions | Journal of Medicinal Chemistry Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b00965/asset/images/large/jm-2017-00965h_0019.jpeg)
Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions | Journal of Medicinal Chemistry
![PDF) Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study PDF) Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study](https://i1.rgstatic.net/publication/317612407_Role_of_N-acetylcysteine_treatment_in_non-acetaminophen-induced_acute_liver_failure_A_prospective_study/links/5953f6e9458515bbaa1e66e3/largepreview.png)
PDF) Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study
![Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia - Caitlin OB Yolland, Donal Hanratty, Erica Neill, Susan L Rossell, Michael Berk, Olivia M Dean, David J Castle, Eric Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia - Caitlin OB Yolland, Donal Hanratty, Erica Neill, Susan L Rossell, Michael Berk, Olivia M Dean, David J Castle, Eric](https://journals.sagepub.com/cms/10.1177/0004867419893439/asset/images/large/10.1177_0004867419893439-fig2.jpeg)
Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia - Caitlin OB Yolland, Donal Hanratty, Erica Neill, Susan L Rossell, Michael Berk, Olivia M Dean, David J Castle, Eric
![Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia | SpringerLink Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00213-019-05382-1/MediaObjects/213_2019_5382_Fig2_HTML.png)
Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia | SpringerLink
![Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study - The Lancet Psychiatry Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study - The Lancet Psychiatry](https://www.thelancet.com/cms/attachment/15fa56e4-c15b-4ed2-a0a4-f1613e0ea94f/gr1_lrg.jpg)
Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study - The Lancet Psychiatry
![Frontiers | N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study Frontiers | N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study](https://www.frontiersin.org/files/Articles/496982/fneur-11-00088-HTML/image_m/fneur-11-00088-g001.jpg)
Frontiers | N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study
![Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review - ScienceDirect Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0149763415001190-gr1i.jpg)
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review - ScienceDirect
Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration | Journal of Medicinal Chemistry
![Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders | Chemical Reviews Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders | Chemical Reviews](https://pubs.acs.org/cms/10.1021/cr050263h/asset/images/large/cr050263hf00014.jpeg)
Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders | Chemical Reviews
![21st ISoP Annual Meeting “A New Era of Pharmacovigilance: Challenges and Opportunities” 20–23 September 2022 Verona, Italy | SpringerLink 21st ISoP Annual Meeting “A New Era of Pharmacovigilance: Challenges and Opportunities” 20–23 September 2022 Verona, Italy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40264-022-01219-7/MediaObjects/40264_2022_1219_Figa_HTML.png)
21st ISoP Annual Meeting “A New Era of Pharmacovigilance: Challenges and Opportunities” 20–23 September 2022 Verona, Italy | SpringerLink
![Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia | SpringerLink Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00213-019-05382-1/MediaObjects/213_2019_5382_Fig3_HTML.png)
Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia | SpringerLink
![PDF) Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology PDF) Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology](https://i1.rgstatic.net/publication/311472703_Treatment-Resistant_Schizophrenia_Treatment_Response_and_Resistance_in_Psychosis_TRRIP_Working_Group_Consensus_Guidelines_on_Diagnosis_and_Terminology/links/584bd81808aed95c24fc011d/largepreview.png)
PDF) Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
![PDF) N -Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms PDF) N -Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms](https://i1.rgstatic.net/publication/362153922_N_-Acetylcysteine_NAC_in_Schizophrenia_Resistant_to_Clozapine_A_Double-Blind_Randomized_Placebo-Controlled_Trial_Targeting_Negative_Symptoms/links/637f80297b0e356feb7c67e9/largepreview.png)
PDF) N -Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms
![RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials | SpringerLink RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00228-018-2595-1/MediaObjects/228_2018_2595_Fig2_HTML.png)
RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials | SpringerLink
UNIVERSIDADE DE LISBOA FACULDADE DE FARMÁCIA STUDY OF THE UNDERLYING BASIS FOR VALPROATE HEPATOTOXICITY: DRUG METABOLISM AND
![RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials | SpringerLink RETRACTED ARTICLE: Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00228-018-2595-1/MediaObjects/228_2018_2595_Fig1_HTML.png)